Article Versions Notes

Zafar A, Alruwaili NK, Imam SS, Yasir M, Alsaidan OA, Alquraini A, Rawaf A, Alsuwayt B, Anwer MK, Alshehri S, et al. Development and Optimization of Nanolipid-Based Formulation of Diclofenac Sodium: In Vitro Characterization and Preclinical Evaluation. Pharmaceutics. 2022; 14(3):507. https://doi.org/10.3390/pharmaceutics14030507

Zafar, Ameeduzzafar, Nabil K Alruwaili, Syed Sarim Imam, Mohd Yasir, Omar Awad Alsaidan, Ali Alquraini, Alenazy Rawaf, Bader Alsuwayt, Md. Khalid Anwer, Sultan Alshehri, and et al. 2022. "Development and Optimization of Nanolipid-Based Formulation of Diclofenac Sodium: In Vitro Characterization and Preclinical Evaluation" Pharmaceutics 14, no. 3: 507. https://doi.org/10.3390/pharmaceutics14030507

Zafar, A., Alruwaili, N. K., Imam, S. S., Yasir, M., Alsaidan, O. A., Alquraini, A., Rawaf, A., Alsuwayt, B., Anwer, M. K., Alshehri, S., & Ghoneim, M. M. (2022). Development and Optimization of Nanolipid-Based Formulation of Diclofenac Sodium: In Vitro Characterization and Preclinical Evaluation. Pharmaceutics, 14(3), 507. https://doi.org/10.3390/pharmaceutics14030507